Regeneron's Immunotherapy Is Given Priority Review for Treatment of New Lung Cancer Patients

Regeneron's Immunotherapy Is Given Priority Review for Treatment of New Lung Cancer Patients

The FDA has accepted an application that could expand Libtayo's addressable patient population to include an important niche.